UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~March 31~~April 8, 2026

FORTE BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-38052	26-1243872
(State or Other Jurisdiction of Incorporation)	(~~CommissionFile~~Commission File Number)	(IRS Employer Identification No.)
3060 Pegasus Park Dr. Building 6 Dallas, Texas		75247
(Address of Principal Executive Offices)		(Zip Code)

3060 Pegasus Park Dr.

Building 6

Dallas, Texas

75247

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (310) 618-6994

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	FBRX	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2 1.0201. ~~Financial~~Entry ~~Statements~~into ~~and~~a ~~Exhibits~~Material Definitive Agreement.

On ~~March~~April 318, 2026, Forte Biosciences, Inc. ~~issued~~(the a“Company”) ~~press~~entered ~~release~~into ~~reporting~~an ~~its~~underwriting ~~financial~~agreement ~~results~~(the ~~for~~“Underwriting Agreement”) with Guggenheim Securities, LLC as representative (the ~~fourth~~“Representative”) ~~quarter~~of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and ~~fiscal~~sale ~~year~~in ~~ended~~a ~~December 31~~public offering (the “Offering”) of 5,709,936 ~~2025~~shares of the Company’s common stock, par value $0.001 Aper ~~copy~~share, at a price to the public of $26.27 per share (the ~~press~~“Shares”). ~~release~~The isCompany ~~furnished~~also ~~herewith~~granted asthe ~~Exhibit~~Underwriters ~~99.1~~an option, exercisable for a period of 30 days, to ~~this~~purchase ~~Current~~up ~~Report~~to onan ~~Form~~additional ~~8-K~~856,490 Shares (the “Option”). All of the Shares in the Offering are being sold by the Company.

The ~~information~~gross ~~furnished~~proceeds infrom ~~this Current Report under Item 2.02 and~~ the ~~exhibit~~Offering ~~attached~~are ~~hereto~~expected ~~shall~~to ~~not~~ be ~~deemed~~approximately ~~“filed”~~$150 million ~~for~~before ~~purposes~~deducting ofunderwriting ~~Section 18~~discounts ofand ~~the~~commissions ~~Securities~~and ~~Exchange~~other ~~Act~~offering ~~of 1934~~expenses, asand ~~amended~~assuming ~~(the~~no ~~“Exchange~~exercise ~~Act”),~~of orthe ~~incorporated~~Option by ~~reference~~the inUnderwriters. ~~any~~The ~~filing~~Offering ~~under~~is ~~the~~expected ~~Securities~~to ~~Act~~close ofon ~~1933,~~or asabout ~~amended~~April 10, ~~or the Exchange Act~~2026, ~~except~~subject asto ~~shall~~satisfaction beof ~~expressly~~customary ~~set~~closing ~~forth by specific reference in such a filing~~conditions.

The Company estimates the net proceeds to the Company from this offering will be approximately $141 million (or approximately $162 million if the underwriters’ option to purchase additional shares is exercised in full) after deducting underwriting discounts and commissions.

The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by such parties.

The Offering is being made pursuant to the Company’s effective registration statement on Form S-3 (File No. 333-286226) (the “Registration Statement”), previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”). A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the Offering has been filed with the SEC and a final prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC.

The foregoing description of the terms of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the Underwriting Agreement which is filed as Exhibit 1.1 hereto and is incorporated herein by reference.

A copy of the opinion of Wilson Sonsini Goodrich & Rosati, P.C. relating to the validity of the Shares is filed as Exhibit 5.1 hereto and is incorporated by reference into the Registration Statement.

Item 7.01. Regulation FD Disclosure.

As part of the Offering, argenx BV has made a strategic investment in the Company.

Item 8.01. Other Events.

A copy of the press release announcing the pricing of the Offering is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

Forward Looking Statements

This report contains forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the Company’s current beliefs and expectations. Forward-looking statements in this report include statements regarding the completion and timing of the Offering and the anticipated proceeds from the Offering. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: whether or not the Company will be able to raise capital through the sale of securities or consummate the Offering; the final terms of the Offering; the satisfaction of customary closing conditions; prevailing market conditions; general economic and market conditions as well as geopolitical developments; and other risks. Additional risks, uncertainties, and other information affecting the Company’s business and operating results are contained in the Company’s Annual Report on Form 10-K filed on March 31, 2026, and in its other filings with the SEC. All forward-looking statements in this Current Report on Form 8-K are current only as of the date hereof and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit		Description
99.1		Press Release dated March 31, 2026
1.1		Underwriting Agreement, dated as of April 8, 2026.
5.1		Opinion of Wilson Sonsini Goodrich & Rosati, P.C.
23.1		Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1).
99.1		Press Release dated April 8, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FORTE BIOSCIENCES, INC.

Date: April 1, 2026

/s/ Antony Riley

Date: April 9, 2026

/s/ Antony Riley

Antony Riley Chief Financial Officer

Filing Compare · Forte Biosciences, Inc.